Alpha Cognition (ACOG) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Surrozen (SRZN) has outperformed Alpha Cognition (ACOG) over the past year, gaining 72.6% versus a gain of 20.4%. Surrozen is the larger company by market cap ($275.5 million vs $178.4 million), about 1.5 times the size. Alpha Cognition converts more of its revenue into profit, with a net margin of -202.2% versus -6960.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACOG | SRZN |
|---|---|---|
| Share price | $8.19 | $23.44 |
| Market cap | $178.36M | $275.50M |
| 1-day change | -3.08% | -6.50% |
| YTD return | +26.00% | +3.72% |
| 1-year return | +20.44% | +72.61% |
| 5-year return | — | -76.75% |
| EPS (TTM) | $-1.32 | $-39.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $10.22M | $3.48M |
| Revenue growth (YoY) | — | -67.37% |
| Net income (latest FY) | $-20.67M | $-242.03M |
| Gross margin | 94.10% | — |
| Operating margin | -221.72% | -1210.58% |
| Net margin | -202.24% | -6960.77% |
| 52-week high | $10.14 | $37.83 |
| 52-week low | $4.50 | $11.39 |
| Distance from 52-week high | -19.23% | -38.04% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +119.78% | +106.48% |
| Average volume | 127.06K | 534.47K |
| Shares outstanding | 21.78M | 11.75M |
| Employees | 71 | 44 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed ACOG by 52.2 percentage points over the past year.
- Alpha Cognition is more profitable, keeping -202.2 cents of every revenue dollar as net income versus -6960.8 cents for Surrozen.
About Alpha Cognition
ACOG stock →Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease.
Healthcare · Biotechnology · 71 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Healthcare · Biotechnology · 44 employees
ACOG vs SRZN FAQ
Which is bigger, Alpha Cognition or Surrozen?
Surrozen (SRZN) is larger, with a market capitalization of $275.50M compared with $178.36M for Alpha Cognition (ACOG).
Which stock has performed better over the past year, ACOG or SRZN?
SRZN returned +72.61% over the past 12 months, compared with +20.44% for ACOG (price return, excluding dividends). Past performance does not predict future results.
Are Alpha Cognition and Surrozen in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.